INNV

Analyst Note: InnovAge Holding Corp. (INNV)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

Classification: CONFIRMED-ACTIVE

• Conservative Entry: $8.73
• Current Price: $8.97
• Extension: +2.7% vs. conservative entry
• Breakout Level: The structure implies a breakout occurred at or near the conservative entry of $8.73, establishing the current "confirmed" state.

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Exposure: None Named

As of 2026-06-13, there is no named secular thesis attached to this specific setup. This is a tactical, setup-led name. The conviction must be derived entirely from the quality of the technical structure (the confirmed coil) and the immediate business fundamentals disclosed in the most recent reporting periods. No macro or thematic thesis should be invented to support the trade; the setup itself is the primary driver.

3. Business Overview

Company: InnovAge Holding Corp. Industry: Healthcare / Senior Care Services Business Model: InnovAge operates a PACE (Program of All-Inclusive Care for the Elderly) model. The company provides a comprehensive, all-inclusive suite of medical and supportive services designed to empower older adults to maintain independence within their homes and communities. Under this model, InnovAge is at risk for 100% of healthcare costs incurred with respect to the care of its participants, receiving capitation revenue from Medicare and Medicaid.

Operational Footprint (as of March 31, 2026):

• Participants: Approximately 8,050 PACE participants.
• Centers: 20 PACE centers operating across six states: California, Colorado, Florida, New Mexico, Pennsylvania, and Virginia.
• Acuity: The company manages a higher acuity population with an average Risk Adjustment Factor (RAF) score of 2.52.

Financial Performance & Guidance (Fiscal Year 2026):

• Revenue Guidance: Management raised FY2026 revenue guidance to a range of $950 million to $975 million.
• EBITDA Guidance: Adjusted EBITDA is expected to be in the range of $85 million to $90 million.
• Census: Ending census for FY2026 is projected between 7,900 and 8,100 participants, with member months between 92,900 and 95,700.
• De Novo Losses: Anticipated losses for new centers in FY2026 are estimated between $11.5 million and $13.5 million.
• Revenue Growth: Capitation revenue for the nine months ended March 31, 2026, was $726.9 million, a 15.1% increase year-over-year.

Operational Drivers:

• Cost Management: Lower cost per participant was driven by reduced permanent nursing facility utilization and lower pharmacy expenses following a transition to in-house pharmacy services.
• Expansion: The company ramped up newer de novo centers in Florida (Tampa and Orlando) in FY2025 and entered a joint venture with Tampa General Hospital in August 2025.
• Regulatory Environment:
• California: The California Department of Health Care Services (DHCS) paused PACE applications for all organizations effective November 20, 2025, for a minimum of two years. Additionally, attestations for planned de novo centers in Downey and Bakersfield were suspended due to audits and medical reviews.
• Rate Pressures: Management anticipates Medicare rates to increase approximately 1.5% to 2% in FY2027. However, initial indications suggest these increases may be lower than historical levels. In Colorado, reduced Medicaid premium rate increases are expected for the fiscal year beginning July 1, 2026. Conversely, wage pressures in California (rates effective January 1, 2027) could impact the latter half of the fiscal year.

4. Archetype and Conviction

Archetype: Deep Value Recovery Rationale: The setup aligns with a "Deep Value Recovery" archetype. The company has demonstrated a turnaround in operational efficiency (lower costs per participant) and is raising full-year guidance despite a challenging regulatory environment in its largest market (California). The "recovery" aspect is evidenced by the raised guidance and the transition from de novo losses to a path toward profitability, supported by the high RAF score which typically commands higher capitation rates.

Valuation & Financial Spine:

• Forward Consensus EPS: FY1 (2026) is $0.108; FY2 (2027) is $0.411.
• Market Opportunity: Management estimates a total addressable market of $265 billion based on approximately 2.3 million eligible participants in the U.S.

Conviction Stack:

• Thesis Strength: Low (Tactical only).
• Evidence Quality: High. Recent earnings transcripts and SEC filings provide specific, quantitative guidance and operational metrics.
• Setup Readiness: Confirmed. The breakout has fired, and the price is extending.
• Rerating Potential: Moderate. The raised guidance and improved cost structure provide a fundamental catalyst, though the regulatory headwinds in California limit the speed of expansion.

5. Invalidations, Strengtheners, and Gaps

Invalidation Triggers:

• Fundamental: A significant widening of de novo losses beyond the $13.5 million guidance or a failure to meet the raised revenue/EBITDA targets in the upcoming quarter.
• Regulatory: Further suspension of PACE applications or audits that prevent the opening of the planned de novo centers in California.

Strengtheners:

• Technical: A sustained close above the current price with increasing volume, confirming the breakout.
• Fundamental: Confirmation that the transition to in-house pharmacy services continues to drive margin expansion beyond current expectations.
• Operational: Successful opening of the Florida centers with faster-than-expected ramp-up to profitability.

Evidence Gaps:

• Specifics on California Audit Resolution: While the suspension of attestations is noted, there is no specific timeline or resolution path provided in the available evidence for the DHCS audits in Sacramento and San Bernardino.
• Detailed FY2027 Rate Impact: While management expects modest Medicare rate increases (1.5-2%), the specific impact of the "lower than historical" increases on the bottom line is not quantified in the provided text.
• Cash Position: The evidence does not explicitly detail the current cash balance or liquidity runway relative to the de novo loss burn rate.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key risks: California regulatory headwinds including DHCS pause on applications and suspension of attestations for new centers; potential wage pressures in California effective Jan 2027; de novo centers expected to generate $11.5M-$13.5M in losses for FY2026. Expected path: Management expects to meet raised guidance through operational efficiency and census growth, with the Florida centers ramping up; the stock may consolidate as the market digests the California regulatory pause before pricing in the FY2027 rate environment. Expected horizon: 3 to 6 months to see the impact of the raised guidance and operational metrics on the next earnings cycle.